Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1918-1920

  Mitchell, K F ^a   Taff, H T ^a   Cuevas, M A ^b   Reinicke, E L ^a   Sanchez, H ^a   Andes, D R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF PUERTO RICO AT CAYEY   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA; CELL METABOLISM; FUNGUS GROWTH; HYDROLYSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BETA-GLUCANS; BIOFILMS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL;

EID: 84875146956     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02378-12     Document Type: Article

References (23)

1. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE; Infectious Diseases Society of America. 2004. Clinical infectious disease guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
2. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267.
3. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G, Cauda R, Sanguinetti M. 2007. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45:1843-1850.
4. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance J. Bacteriol. 183: 5385-5394.
5. Ramage G, Rajendran R, Sherry L, Williams C. 2012. Fungal biofilm resistance. Int. J. Microbiol. 2012:528521.
6. Baillie GS, Douglas LJ. 1999. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 310:644-656.
7. LaFleur MD, Kumamoto CA, Lewis K. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50:3839-3846.
8. Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49: 973-980.
9. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340.
10. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46:397-403.
11. Jabra-Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg. Infect. Dis. 10:14-19.
12. Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, Van-Handel M, Andes D. 2007. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520.
13. Nett JE, Sanchez H, Cain MT, Andes DR. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202:171-175.
14. Vediyappan G, Rossignol T, d'Enfert C. 2010. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob. Agents Chemother. 54:2096-2111.
15. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J. Clin. Microbiol. 50:3435-3442.
16. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. 2012. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol. Rev. 36:288-305.
17. Melo AS, Bizerra FC, Freymüller E, Arthington-Skaggs BA, Colombo AL. 2011. Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med. Mycol. 49:253-262.
18. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55(Part 8):999-1008.
19. Taff HT, Nett JE, Zarnowski R, Ross KM, Sanchez H, Cain MT, Hamaker J, Mitchell AP, Andes DR. 2012. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog. 8:e1002848. doi:10.1371/journal.ppat.1002848.
20. Nett JE, Cain MT, Crawford K, Andes DR. 2011. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J. Clin. Microbiol. 49:1426-1433.
21. Taff HT, Nett JE, Andes DR. 2012. Comparative analysis of Candida biofilm quantitation assays. Med. Mycol. 50:214-218.
22. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
23. da Silva WJ, Seneviratne J, Parahitiyawa N, Rosa EA, Samaranayake LP, Del Bel Cury AA. 2008. Improvement of XTT assay performance for studies involving Candida albicans biofilms. Braz. Dent. J. 19:364-369.